Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310375 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT00310375 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 181 participants.
The verdict
NCT00310375, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.
Interventions
- DRUG Ezogabine: USAN Retigabine (International Nonproprietary Name)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310375
The ClinicalTrials.gov registry entry for NCT00310375 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ezogabine: USAN Retigabine (International Nonproprietary Name) is the first listed.
NCT00310375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310375 about?
NCT00310375 is a clinical study titled "Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial". The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of long-term treatment with retigabi...
What is the current status of trial NCT00310375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2006-05-01. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT00310375?
The interventions under investigation include: Ezogabine: USAN Retigabine (International Nonproprietary Name) (DRUG).
Who is sponsoring clinical trial NCT00310375?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.